SEPTEMBER 2024LIFE SCIENCES REVIEW8IN MY OPINIONIN MY OPINIONThe journey to an innovative therapy: CAR-T cellsT cells equipped with a Chimeric Antigen Receptor, known as CAR-T cells, have had an extraordinary impact on the oncology field. Famously recognized in clinical, scientific, and mainstream circles, CAR-T cells have ushered in a new era in the treatment of advanced, relapsed/refractory blood cancers. Many patients, who were enduring the painful realization that they might lose their fight with cancer after conventional methods of cancer treatment had failed, experienced life-restoring transformation upon receiving an infusion of their own CAR-T cells. Over a decade into many CAR-T treatments, we see reports of decade-long sustained remissions which suggest potential cures for diseases that had long been deemed incurable. At the heart of CAR-T cell therapy is an elegantly simple premise: we can harness the intrinsic power of immune cells and equip them with the necessary tools to unleash a destructive force capable of eradicating certain forms of cancer. Despite the appearance of simplicity, the most common method of creating a CAR-T cell involves a complex, extensive, and costly manufacturing process that starts with the extraction of the patient's own T cells. This poses the first challenge. Patients with advanced, metastatic cancers have often received multiple lines of therapy prior to CAR-T, and, as a result, are rendered immunocompromised, possessing fewer T cells that are weaker in function. Taking these cells through the required genetic editing steps and rapid expansion phase constitutes a new set of challenges. Not all manufactures succeed, and thus, not all patients, unfortunately, receive their therapy. In a relatively short amount of time, clinicians and scientists have advanced the concept of transforming one's own immune cells into potent anti-cancer agents and moved rapidly toward bringing these innovative therapies to hospitals around the world. CONQUERING CHALLENGES AND BROADENING OPPORTUNITIES: THE JOURNEY TO BRINGING INNOVATIVE CELL THERAPIES TO PATIENTSBy Tamara J. Laskowski, Global Head, Clinical & Process Development, Lonza Personalized Medicine, LonzaTamara J. Laskowski
< Page 7 | Page 9 >